CLINICAL POLICY



Request for Medically Necessary Drug Not on the Statewide Preferred Drug List

Clinical Policy: Request for Medically Necessary Drug Not on the Statewide Preferred Drug List

Reference Number: PA.CP.PMN.16

Effective Date: 01/2018

Last Review Date: 07/2023

Coding Implications
Revision Log

Description

The intent of the criteria is to ensure that patients follow selection elements established by PA Health & Wellness medical policy for drugs that are not on the Statewide preferred drug list (PDL).

FDA approved indication

N/A

Policy/Criteria

It is the policy of Pennsylvania Health and Wellness[®], that drugs that are not listed on the Statewide PDL are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria

A. Request for a Drug NOT on the Statewide PDL where Custom Coverage Criteria

Exist: Please refer to the custom coverage criteria policy corresponding to the medication and the indicated use

B. Request for a Drug NOT on the Statewide PDL for a Labeled Use without Coverage Criteria (must meet all):

- 1. Request is for a drug without custom coverage criteria;
- 2. Failure of an adequate trial of at least two FDA-approved drugs for the indication and/or drugs that are considered the standard of care, when such agents exist, at maximum indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
- 3. If request is for combination product or alternative dosage form or strength of existing drugs (except combination HIV antiretrovirals), medical justification* supports inability to use the individual drug products concurrently or alternative dosage forms or strengths (e.g., contraindications to the excipients of all alternative products);
 - *Use of a copay card or discount card does not constitute medical necessity
- 4. Member has no contraindications to prescribed agent per the product information label;
- 5. If applicable, prescriber has taken necessary measures to minimize any risk associated with a boxed warning in the product information label;
- 6. Treatment is not for a benefit-excluded purpose (e.g., cosmetic);
- 7. Request meets one of the following (a or b):

CLINICAL POLICY



Request for Medically Necessary Drug not on the PDL

- a. Dose does not exceed the FDA approved maximum recommended dose for the relevant indication and health plan approved daily quantity limit;
- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: duration of request or 6 months (whichever is less)

C. Request for a Drug NOT on the Statewide PDL for an Off-label Use (i.e. utilization of an FDA-approved drug for uses other than those listed in the FDA-approved labeling or in treatment regimens or populations that are not included in approved labeling) where No Custom Coverage Criteria Exist: Please refer to PA.CP.PMN.53 Off-Label Use of Drugs Not on the Statewide Preferred Drug List

II. Continued Therapy

- A. Request for a Drug NOT on the Statewide PDL where Custom Coverage Criteria Exist: Please refer to the custom coverage criteria policy corresponding to the medication and the indicated use
- **B.** Request for a Drug NOT on the Statewide PDL for a Labeled Use without Coverage Criteria (must meet 1 or 2):
 - 1. Currently receiving medication via PA Health & Wellness benefit, or member has previously met all initial approval criteria or the Continuity of Care policy (PA.LTSS.PHARM.01) applies;
 - 2. Member is responding positively to therapy or provider feels necessary to continue requested medication;
 - 3. If request is for a dose increase, request meets one of the following (a or b):
 - a. New dose does not exceed the FDA-approved maximum recommended dose for the relevant indication and health plan approved daily quantity limit;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: 12 months

C. Request for a Drug NOT on the Statewide PDL for an Off-label Use (i.e. utilization of an FDA-approved drug for uses other than those listed in the FDA-approved labeling or in treatment regimens or populations that are not included in approved labeling) where No Custom Coverage Criteria Exist: Please refer to PA.CP.PMN.53 Off-Label Use of Drugs Not on the Statewide Preferred Drug List

III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key FDA: Food and Drug Administration HIV: human immunodeficiency virus

PDL: preferred drug list



CLINICAL POLICY

Request for Medically Necessary Drug not on the PDL

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2018: replacing retired policy PA.CP.PST.16	10/2018	
09/01/2019 submission for statewide PDL implementation 01/01/2020: Policy Name revised to reflect its use only for drugs NOT listed on the statewide PDL 4Q 2020 annual review: added bypass of required preferred agent trials if clinically significant adverse effects are experienced or all are contraindicated; dose requirements and positive response added	09/2019	
4Q 2021 annual review: no significant changes	10/2021	
4Q 2022 annual review: no significant changes.	10/2022	
Added renewal criteria provider feels necessary to continue	07/2023	